ETF今日收评 | 科创创新药ETF涨超7%，通信相关ETF跌超5%

Market Overview - The market experienced a downward trend throughout the day, with all three major indices declining. The pharmaceutical sector showed resilience with an increase, while the software sector was active. Conversely, computing hardware and chip-related stocks faced collective declines [1]. ETF Performance - The Sci-Tech Innovation Drug ETF surged over 7%, indicating strong investor interest in the pharmaceutical innovation sector [1]. - Specific ETFs and their performance include: - Huatai-PineBridge Sci-Tech Innovation Drug ETF: 0.922, up 7.71% [2] - Guotai Junan Sci-Tech Innovation Drug ETF: 0.989, up 7.27% [2] - Hong Kong Stock Connect Innovation Drug ETF: 1.756, up 5.78% [2] - Other ETFs in the innovation drug category also showed positive performance, with increases ranging from 5.1% to 5.78% [2]. Industry Insights - Analysts suggest that China's innovative drug industry is integrating robustly into the global pharmaceutical innovation system. Over the past decade, the industry has shifted from a focus on generic drugs to a significant increase in business development (BD) transactions in global innovative drugs. This transition reflects a move from "following" and "keeping pace" to "leading" in certain areas, supported by policy, clinical breakthroughs, and capital [2].